Rituximab in IgG4-RD: A Phase 1-2 Trial

NCT01584388 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Retroperitoneal Fibrosis
Autoimmune Pancreatitis
Sialadenitis
Pseudotumor

Interventions

DRUG: Rituximab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]